Welcome to LookChem.com Sign In|Join Free
  • or

341031-54-7

Post Buying Request

341031-54-7 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Sunitinib malate
Cas No: 341031-54-7
USD $ 5.0-5.0 / Gram 1 Gram 100 Kilogram/Day Hangzhou Share Chemical Co., Ltd Contact Supplier
Sunitinib malate 341031-54-7
Cas No: 341031-54-7
No Data 10 Gram 1000 Gram/Month Taizhou Crene Biotechnology co.ltd Contact Supplier
Sunitinib malate CAS NO.341031-54-7
Cas No: 341031-54-7
No Data 1 Kilogram 500~1000 Kilogram/Month Hubei Jusheng Technology Co., Ltd., Contact Supplier
High purity Various Specifications Sunitinib malate CAS:341031-54-7
Cas No: 341031-54-7
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
Sunitinib malate
Cas No: 341031-54-7
No Data 10 Gram 5000 Kilogram/Month Hubei Yuancheng Saichuang Technology Co., Ltd Contact Supplier
High quality Sunitinib Malate supplier in China
Cas No: 341031-54-7
No Data No Data No Data Simagchem Corporation Contact Supplier
Sunitinib Malate CAS No 341031-54-7
Cas No: 341031-54-7
USD $ 1.0-2.0 / Metric Ton 5 Metric Ton 2500 Metric Ton/Year Henan Sinotech Import&Export Corporation Contact Supplier
Sunitinib malate
Cas No: 341031-54-7
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-10 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Sunitinib malate
Cas No: 341031-54-7
USD $ 2.0-2.0 / Gram 5 Gram 5 Kilogram/Month Wuhan Sunrise Technology development company limited Contact Supplier
Hot sale Sunitinib Malate with best price and high quality
Cas No: 341031-54-7
USD $ 390.0-660.0 / Kilogram 1 Kilogram 200 Metric Ton/Month Crovell Biotech (Hebei) Co., Ltd. Contact Supplier

341031-54-7 Usage

Anticancer drug

Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Uses

Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

Uses

Anti-cancer drugs

Uses

A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.

Uses

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit

Chemical Properties

Yellow Solid

Biological Activity

Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Brand name

(Pfizer).

341031-54-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name Sunitinib Malate

1.2 Other means of identification

Product number -
Other names sunitynib L-malate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:341031-54-7 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields